Drug intelligence / Profile preview

malaria vaccine (messenger RNA-lipid nanoparticle)

Development stage: Preclinical
Lead developer: eTheRNA immunotherapies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The malaria vaccine (messenger RNA-lipid nanoparticle) is an investigational mRNA-based vaccine candidate being developed by eTheRNA immunotherapies for the prevention of malaria. The vaccine utilizes a messenger RNA (mRNA) platform encapsulated within lipid nanoparticles (LNPs) to deliver genetic instructions for malaria-specific antigens into host cells. Once expressed, these antigens are intended to stimulate a robust and protective immune response, including both antibody and T-cell mediated immunity, against *Plasmodium* parasites. The program is currently in the preclinical stage of development and is designed for intramuscular administration.

Other names: mRNA-LNP Malaria VaccineMalaria vaccine

Beyond the preview

Go deeper on malaria vaccine (messenger RNA-lipid nanoparticle).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on malaria vaccine (messenger RNA-lipid nanoparticle).

Explore the full profile